{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T18:37:17Z","timestamp":1762627037382,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.retram.2025.103500","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T12:16:42Z","timestamp":1738844202000},"page":"103500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Denutrition status prevails over a standard AML risk assessment in older adults"],"prefix":"10.1016","volume":"73","author":[{"given":"Laura","family":"Simon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Caulier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Berthon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Harrivel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magalie","family":"Joris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Leduc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Duployez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Preudhomme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Marolleau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4073-1559","authenticated-orcid":false,"given":"Delphine","family":"Lebon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.retram.2025.103500_bib0001","unstructured":"SPF survie des personnes atteintes de cancer en France m\u00e9tropolitaine 1989-2018 - leuc\u00e9mies aig\u00fces myelo\u00efdes. https:\/\/www.santepubliquefrance.fr\/import\/survie-des-personnes-atteintes-de-cancer-en-france-metropolitaine-1989-2018-leucemies-aiguees-myeloides. Accessed 19 Sep 2024."},{"key":"10.1016\/j.retram.2025.103500_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106727","article-title":"A concise review on the molecular genetics of acute myeloid leukemia","volume":"111","author":"Padmakumar","year":"2021","journal-title":"Leuk Res"},{"key":"10.1016\/j.retram.2025.103500_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2021.101320","article-title":"Effectiveness of allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia","volume":"34","author":"Appelbaum","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.retram.2025.103500_bib0004","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of acute myeloid leukemia diagnosis and pathways","volume":"35","author":"Bullinger","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.retram.2025.103500_bib0005","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.retram.2025.103500_bib0006","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.retram.2025.103500_bib0007","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.retram.2025.103500_bib0008","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.retram.2025.103500_bib0009","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.retram.2025.103500_bib0010","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.retram.2025.103500_bib0011","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.retram.2025.103500_bib0012","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.retram.2025.103500_bib0013","unstructured":"An evaluation of 17 years of low dose cytarabine as therapy for AML patients not fit for intensive treatment, including patients with adverse cytogenetics, shows improving survival, potential underutilisation and highlights the need for new therapy | Cochrane Library. doi: 10.1002\/central\/CN-01453009\/full. Accessed 19 Sep 2024."},{"key":"10.1016\/j.retram.2025.103500_bib0014","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1634\/theoncologist.2008-0224","article-title":"Acute myelogenous leukemia in older adults","volume":"14","author":"Klepin","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.retram.2025.103500_bib0015","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2020008812","article-title":"Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia","volume":"138","author":"Sorror","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.retram.2025.103500_bib0016","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3390\/cancers15041002","article-title":"Combining the HCT-CI, G8, and AML-Score for fitness evaluation of elderly patients with acute myeloid leukemia: a single center analysis","volume":"15","author":"Aydin","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.retram.2025.103500_bib0017","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/hon.2543","article-title":"Serum albumin or body mass index: which prognostic factor for survival in patients with acute myeloblastic leukaemia?","volume":"37","author":"Filliatre-Clement","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.retram.2025.103500_bib0018","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/hon.2925","article-title":"Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemia","volume":"39","author":"Doucette","year":"2021","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.retram.2025.103500_bib0019","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.3390\/cancers15082399","article-title":"Optimizing treatment options for newly diagnosed acute myeloid leukemia in older patients with comorbidities","volume":"15","author":"Oshikawa","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.retram.2025.103500_bib0020","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3892\/ol.2024.14362","article-title":"Low\u2011dose venetoclax combined with azacitidine in older and frail patients with newly diagnosed acute myeloid leukaemia","volume":"27","author":"Rong","year":"2024","journal-title":"Oncol Lett"},{"key":"10.1016\/j.retram.2025.103500_bib0021","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/oncolo\/oyac135","article-title":"Venetoclax and hypomethylating agents as first-line treatment in newly diagnosed patients with AML in a predominately community setting in the US","volume":"27","author":"Vachhani","year":"2022","journal-title":"Oncologist"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318625000091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318625000091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T18:34:26Z","timestamp":1762626866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318625000091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2452318625000091"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2025.103500","relation":{},"ISSN":["2452-3186"],"issn-type":[{"type":"print","value":"2452-3186"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Denutrition status prevails over a standard AML risk assessment in older adults","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2025.103500","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"103500"}}